Enlivex Therapeutics (Enlivex Therapeutics) 3-Year EBITDA Growth Rate : -11.80% (As of Sep. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Enlivex Therapeutics 3-Year EBITDA Growth Rate?

Enlivex Therapeutics's EBITDA per Share for the three months ended in Sep. 2023 was $-0.29.

During the past 3 years, the average EBITDA Per Share Growth Rate was -11.80% per year. During the past 5 years, the average EBITDA Per Share Growth Rate was 19.80% per year. During the past 10 years, the average EBITDA Per Share Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 12 years, the highest 3-Year average EBITDA Per Share Growth Rate of Enlivex Therapeutics was 70.90% per year. The lowest was -272.20% per year. And the median was 25.65% per year.

Competitive Comparison of Enlivex Therapeutics's 3-Year EBITDA Growth Rate

For the Biotechnology subindustry, Enlivex Therapeutics's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Enlivex Therapeutics's 3-Year EBITDA Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Enlivex Therapeutics's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Enlivex Therapeutics's 3-Year EBITDA Growth Rate falls into.

Enlivex Therapeutics 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Enlivex Therapeutics (NAS:ENLV) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Enlivex Therapeutics 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Enlivex Therapeutics's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Enlivex Therapeutics (Enlivex Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Enlivex Therapeutics Ltd (NAS:ENLV) » Definitions » 3-Year EBITDA Growth Rate

Comparable Companies

Traded in Other Exchanges

ENLV:Israel 1BT:Germany

Address

14 Einstein Street, Nes Ziona, ISR, 7403618

Website

https://www.enlivex.com

Enlivex Therapeutics Ltd is an Israel-based development-stage biopharmaceutical company. It is focused on developing and commercializing an allogeneic drug pipeline for rebalancing immune hyper-responses. The company's Allocetra is an immunotherapy that is being developed to rebalance a life-threatening unbalanced immune system, using the immune system's own natural regulation mechanisms.